Indaptus Therapeutics Inc (INDP) Stock AnalysisINDPStock AnalysisIndaptus Therapeutics Inc

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Indaptus Therapeutics Inc is not a good buy right now due to its significant financial losses and declining stock performance. The current price is $1.14, which is down 58.39% year-to-date. Additionally, the company has a negative EPS of -0.02 and a forward P/E of 0, indicating no earnings growth expected in the near term. The main risk is the high volatility reflected in a 5-day change of -11.63% and a 1-year change of -81.47%.